Acrivon Therapeutics Inc (ACRV) - News Archive

In the dynamic field of cancer therapeutics, pioneering research and early-stage clinical trials are crucial steps in the development of novel treatment options. Acrivon Therapeutics, a biotechnology company committed t...

Acrivon Therapeutics: Positive Progress Amid Market VolatilityAcrivon Therapeutics, Inc. a clinical-stage precision medicine company based in Watertown, Massachusetts, has made notable strides in cancer treatment and dr...

Acrivon Therapeutics Announces Groundbreaking Developments: Positive Phase 2 Data and Promising Pipeline Progress Webcast Investor Event to Highlight Encouraging Clinical Data and Advancements in Predictive Precision Pr...

Acrivon Therapeutics, a leading pharmaceutical company, presented initial positive clinical data for their investigational drug ACR-368 and highlighted progress in their pipeline program at a recent Corporate R&D event....

Acrivon Therapeutics, a leading biopharmaceutical company focused on innovative cancer therapies, recently presented groundbreaking data at the prestigious American Association for Cancer Research (AACR) Annual Meeting....

Acrivon Therapeutics, a pioneering biopharmaceutical company, has made significant strides in the field of precision oncology. With its proprietary proteomics-based patient responder identification platform, Acrivon Pre...

In a groundbreaking development, Acrivon Therapeutics, a leading biotechnology company, has recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for their ACR-3...

WATERTOWN, Mass., Nov. 21, 2023 - Acrivon Therapeutics, a leading clinical stage biopharmaceutical company in the field of precision oncology medicines, recently announced the approval of a grant of equity award to one...